Skip Navigation



NDT Advance Access published online on November 17, 2008
Nephrology Dialysis Transplantation, doi:10.1093/ndt/gfn616
This Article
Right arrow Extract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
24/2/338    most recent
gfn616v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Haneda, M.
Right arrow Articles by Morikawa, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Haneda, M.
Right arrow Articles by Morikawa, A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2008]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org


Which hypoglycaemic agents to use in type 2 diabetic subjects with CKD and how?*

Masakazu Haneda1 and Akizuki Morikawa2

1 Department of Medicine, Division of Metabolism and Biosystemic Science, Asahikawa Medical College 2 Asahikawa Red Cross Hospital, Asahikawa, Hokkaido, Japan

Correspondence and offprint requests to: Masakazu Haneda, Department of Medicine, Division of Metabolism and Biosystemic Science, Asahikawa Medical College, Midorigaokahigashi 2-1-1-1, Asahikawa, Hokkaido 078-8510, Japan. Tel: +81-166-68-2450; Fax: +81-166-68-2459; E-mail: haneda{at}asahikawa-med.ac.jp

Keywords: diabetes mellitus; diabetic nephropathy; glycated albumin; HbA1c; hypoglycaemia

DCCT [1], UKPDS [2,3] and Kumamoto studies [4] clearly indicate that good glycaemic control can reduce the risk of nephropathy in subjects with both type 1 and type 2 diabetes. Furthermore, the recent ADVANCE trial confirmed that much tighter glycaemic control (mean HbA1c = 6.5%) is beneficial for nephropathy in subjects with type 2 diabetes [5]. In order to achieve tight glycaemic control, we would like to try to describe which hypoglycaemic agents to use in type 2 diabetic subjects with CKD and how, in this comment.



   Type 2 diabetic subjects with CKD stage 1 or 2
Top
 Type 2 diabetic subjects...
Type 2 diabetic subjects...
 Conclusion
 References
 
There is no limitation to use any hypoglycaemic agent in this stage of subjects. However, from UKPDS, it was suggested to start with metformin for obese subjects and sulfonylureas for non-obese subjects [2,3]. This concept was used in Steno-2 trials for type 2 diabetic subjects with microalbuminuria [6]. In 2006, a consensus algorism for the initiation and adjustment of the treatment with hypoglycaemic agents was proposed from ADA and EASD [7]. This algorism recommended to use metformin with life-style intervention first and to add basal insulin (most effective), sulfonylurea (least expensive) or glitazones (no hypoglycaemia), if HbA1c values still exceeded 7.0%. However, after this algorism was developed, concerns about increased risk of myocardial infarction with the use of rosiglitazone were raised [8] and other medications such as glinides, {alpha}-glucosidase inhibitors, GLP-1 analogues and DPP4 inhibitors were not included owing to less glucose-lowering effectiveness, limited clinical data and/or relative expense [9]. Meanwhile, the ADOPT study, which examined the glycaemic durability of monotherapy, was published [10]. The results indicate that monotherapy failure was more frequent in glybride than metformin or rosiglitazone. However, the cardiovascular event was less frequent in the glyburide group. Thus, the authors stated that the potential risks and benefits, the profile of adverse events and the costs of the drugs should all be considered [10]. In the case of insulin, ADA recommended to initiate that at the time of diagnosis for individuals presenting with weight loss or other severe hyperglycaemic symptoms or signs [9].

Type 2 diabetes is recently considered as a progressive disorder. The UKPDS [11] and ADOPT [10] studies indicate progressive loss of β-cell function during the study periods. An autopsy study also clearly indicates that β-cell volume was decreased and apoptosis of β-cells was increased in type 2 diabetic subjects [12]. Therefore, in the next decade, it is necessary to develop the method not only to achieve good glycaemic control but also to preserve β-cell function by inhibiting the apoptosis or inducing regeneration.



   Type 2 diabetic subjects with CKD stages 3–5
Top
 Type 2 diabetic subjects...
 Type 2 diabetic subjects...
Conclusion
 References
 
The beneficial effect of tight glycaemic control itself on diabetic nephropathy in CKD stages 3–5 has unfortunately not been established yet. However, if blood pressure was controlled, good glycaemic control was shown to be associated with reduced GFR decline [13]. Furthermore, glycaemic control is generally considered to be important in the prevention of other diabetic complications, such as retinopathy, neuropathy or macroangiopathy. Indeed, even in diabetic subjects on maintenance haemodialysis, poor glycaemic control was shown to be associated with increased risk of mortality [14,15]. Therefore, it is important to keep good glycaemic control in diabetic subjects with CKD stages 3–5.

In diabetic subjects with CKD, there are several factors that influence the glycaemic status and/or insulin action. First, insulin resistance will appear in a relatively early stage of CKD and increase the risk of hyperglycaemia. In contrast, renal gluconeogenesis is impaired and the clearance of insulin and other hypoglycaemic agents is delayed, thus increasing the risk of hypoglycaemia [16]. The latter will make a serious problem.

We have a large emergency unit in Asahikawa Red Cross Hospital. During the last one and a half years, 57 cases were with consciousness disturbance due to severe hypoglycaemia in a total of 6276 emergency cases (0.9%). Forty-eight cases were drug-induced hypoglycaemia (3 with type 1 diabetes and 45 with type 2 diabetes), 60.4% of which occurred in subjects older than 70. Twenty-five cases were insulin-induced hypoglycaemia and 23 cases were due to sulfonylurea. In elderly subjects (>70), sulfonylurea-induced hypoglycaemia occurred in more than 60%. Initial levels of serum creatinine were available in 34 cases. As shown in Figure 1, in elderly subjects (>70), hypoglycaemia occurred more frequently (>60%) in subjects with CKD stages 3–5. Therefore, we should be very careful in treating elderly diabetic subjects with CKD stages 3–5.


Figure 1
View larger version (14K):
[in this window]
[in a new window]
[Download PowerPoint slide]
  		Fig. 1 The consciousness disturbance due to severe hypoglycaemia in elderly subjects (>70) occurs frequently in subjects with CKD stages 3–5. Open circle indicates insulin-induced hypoglycaemia and closed circle indicates sulfonylurea-induced hypoglycaemia. eGFR was calculated using the formula in [28].

 
How to use hypoglycaemic agents in type 2 diabetic subjects with CKD stages 3–5 is briefly described below. However, it should be noticed that the pharmacokinetics of each agent was examined in a small group of subjects and there is a substantial individual variation in the half-life of each agent. Moreover, the long-term data examining the safety of hypoglycaemic agents in diabetic subjects with CKD stages 3–5 are not available.

Insulin secretagogues
Sulfonylureas
First-generation sulfonylureas are rarely used and should be avoided in subjects with CKD stages 3–5. Among second-generation sulfonylureas, glibenclamide (glyburide) undergoes oxidation by the liver to three major metabolites. One of them (4-hydroxy-glibenclamide) has ~15% of the potency of glibenclamide itself and excreted in the urine [17]. Thus, the risk of hypoglycaemia is increased in subjects with reduced renal function. Glipizide and gliclazide are metabolized by the liver to several inactive metabolites and thus generally considered to be used in subjects with reduced renal function [18]. Glimepiride, one of the agents frequently used worldwide, is metabolized in the liver to two metabolites, one of which is weakly active and excreted in the urine, thus increasing the risk of hypoglycaemia in subjects with reduced renal function [16].

Glinides
Glinides are the insulin secretagogues with a short half-life and duration of action. They have modest glycaemic efficacy and a relatively low risk of hypoglycaemia. A small amount of nateglinide is excreted in the urine, and its active metabolite is also excreted in the urine [16,18]. Thus, in the advanced stage of CKD, nateglinide has an increased risk of hypoglycaemia. Other glinides, rapaglinide and mitiglinide, are considered to be used in subjects with CKD.

Incretin-based insulin secretagogues
These include GLP-1 receptor agonists and DPP-4 inhibitors. Since these are a new class of agents, long-term safety in subjects with CKD has not been determined. However, excenatide, one of GLP-1 receptor agonists, is cleared by the kidney and its use in subjects with advanced CKD is not recommended or tolerated [16]. Sitagliptin, one of DPP-4 inhibitors, is excreted in the urine and thus reduced doses are recommended in subjects with CKD stages 3–5 [19].

Insulin sensitizer
Biguanides
The most common side effect is gastrointestinal disturbance, and it is well known that metformin can cause lactic acidosis. Since metformin is excreted unchanged in the urine, it is accumulated with the reduction of renal function. Thus, the use of metformin is considered to be contraindicated in subjects with CKD stages 3–5.

Thiazolidinediones
The data of pharmacokinetics of thiazolidinediones, rosiglitazone and pioglitazone, indicate that they can be used without dose adjustment in subjects with CKD [20,21]. However, fluid retention is one of the side effects of thiazolidinediones. Therefore, these agents need to be carefully used in subjects with CKD.

{alpha}-Glucosidase inhibitors
Acarbose and voglibose are essentially not absorbed, while almost 50% of miglitol are absorbed. Although they act in the intestine, the use of {alpha}-glucosidase inhibitors in subjects with advanced CKD is generally not recommended [16,18].

Insulin
The use of insulin, human or analogue, is recommended in diabetic subjects with CKD stages 3–5. However, the dose of insulin needs to be reduced in the advanced stage of CKD, because exogenously administrated insulin is mainly eliminated by the kidney. The American College of Physicians recommended a 25% decrease in doses of insulin when GFR decreased to between 50 and 10 mL/min, and a 50% decrease when GFR decreased to <10 mL/min [22,23]. Self-monitoring of blood glucose (SMBG) will help make this adjustment. The target HbA1c will be <7.0% in this group of subjects, because the recent report indicates that HbA1c levels >7.3% at the baseline significantly increase the risk of death in diabetic subjects under haemodialysis [24].

How to evaluate the status of glycaemic control in subjects with ESRD
HbA1c values are generally used to evaluate glycaemic control all over the world. However, in subjects with ESRD, there are some problems. Recent reports indicate that HbA1c levels underestimate glycaemic control in diabetic subjects with haemodialysis due to renal anaemia and the use of erythropoietin [25,26]. Since the levels of glycated albumin are not affected by these factors, glycated albumin might be a better marker of glycaemic control in diabetic subjects under haemodialysis with renal anaemia treated with erythropoietin [25,26]. Indeed, better survival in subjects with low glycated albumin has recently been reported [27].



   Conclusion
Top
 Type 2 diabetic subjects...
 Type 2 diabetic subjects...
 Conclusion
References
 
In type 2 diabetic subjects with the early stage of CKD, all hypoglycaemic agents can be applicable. However, in subjects with the advanced stage of CKD, some of the drugs are contraindicated and others need to be used with caution in a reduced dose because of the increased risk of hypoglycaemia. In that case, switching to insulin with SMBG will be recommended. The dose of insulin needs to be reduced in the advanced stage of CKD.

Conflict of interest statement. None declared.



   Notes
 
* The content of this comment was presented in the symposium of 11th Asian Pacific Congress of Nephrology held in Kuala Lumpur, 5–8 May 2008. Back



   References
Top
 Type 2 diabetic subjects...
 Type 2 diabetic subjects...
 Conclusion
 References
 

  1. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes. N Engl J Med (1993) 329:977–986.[Abstract/Free Full Text]
  2. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet (1998) 352:837–853.[CrossRef][Web of Science][Medline]
  3. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet (1998) 352:854–865.[CrossRef][Web of Science][Medline]
  4. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract (1995) 28:103–117.[CrossRef][Web of Science][Medline]
  5. The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med (2008) 358:2560–2572.[Abstract/Free Full Text]
  6. Gaede P, Vedel P, Parving HH, et al. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. Lancet (1999) 353:617–622.[CrossRef][Web of Science][Medline]
  7. Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes. A consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care (2006) 29:1963–1972.[Free Full Text]
  8. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med (2007) 356:2457–2471.[Abstract/Free Full Text]
  9. American Diabetes Association. Standards of medical care in diabetes-2008. Diabetes Care (2008) 31(Suppl_1):S12–S54.[Free Full Text]
  10. Kahn SE, Haffner SM, Heise MA, et al, ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med (2006) 355:2427–2443.[Abstract/Free Full Text]
  11. U.K. Prospective Diabetes Study Group. U.K. prospective diabetes study 16. Overview of 6 years’ therapy of type II diabetes: a progressive disease. Diabetes (1995) 44:1249–1258.[Abstract]
  12. Butler AE, Janson J, Bonner-Weir S, et al. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes (2003) 52:102–110.[Abstract/Free Full Text]
  13. Alaveras AE, Thomas SM, Sagriotis A, et al. Promoters of progression of diabetic nephropathy: the relative roles of blood glucose and blood pressure control. Nephrol Dial Transplant (1997) 12(Suppl 2):71–74.[Abstract/Free Full Text]
  14. Oomichi T, Emoto M, Tabata T, et al. Impact of glycemic control on survival of diabetic patients on chronic regular hemodialysis: a 7-year observational study. Diabetes Care (2006) 29:1496–1500.[Abstract/Free Full Text]
  15. Kalantar-Zadeh K, Kopple JD, Regidor DL, et al. A1C and survival in maintenance hemodialysis patients. Diabetes Care (2007) 30:1049–1055.[Abstract/Free Full Text]
  16. Lubowsky ND, Siegel R, Pittas AG. Management of glycemia in patients with diabetes mellitus and CKD. Am J Kidney Dis (2007) 50:865–879.[CrossRef][Web of Science][Medline]
  17. Harrower AD. Pharmacokinetics of oral antihyperglycaemic agents in patients with renal insufficiency. Clin Pharmacokinet (1996) 31:111–119.[Web of Science][Medline]
  18. KDOQI. Clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Guideline 2: Management of hyperglycemia and general diabetes care in chronic kidney disease. Am J Kidney Dis (2007) 49(Suppl 2):S62–S73.
  19. Bergman AJ, Cote J, Yi B, et al. Effect of renal insufficiency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-4 inhibitor. Diabetes Care (2007) 30:1862–1864.[Free Full Text]
  20. Agrawal A, Sautter MC, Jones NP. Effects of rosiglitazone maleate when added to a sulfonylurea regimen in patients with type 2 diabetes mellitus and mild to moderate renal impairment: a post hoc analysis. Clin Ther (2003) 25:2754–2764.[CrossRef][Web of Science][Medline]
  21. Budde K, Neumayer HH, Fritsche L, et al. The pharmacokinetics of pioglitazone in patients with impaired renal function. Br J Clin Pharmacol (2003) 55:368–374.[CrossRef][Web of Science][Medline]
  22. Aronoff GR, Berns JS, Brier ME, et al. Drug prescribing in renal failure. In: Dosing Guidelines for Adults (1999) 4th edn. Philadelphia: American College of Physicians. 84.
  23. Charpentier G, Riveline JP, Varroud-Vial M. Management of drugs affecting blood glucose in diabetic patients with renal failure. Diabetes Metab (2000) 26:73–85.[Web of Science][Medline]
  24. Hayashino Y, Fukuhara S, Akiba T, et al. Diabetes, glycaemic control and mortality risk in patients on haemodialysis: the Japan dialysis outcomes and practice pattern study. Diabetologia (2007) 50:1170–1177.[CrossRef][Web of Science][Medline]
  25. Inaba M, Okuno S, Kumeda Y, et al, Osaka CKD Expert Research Group. Glycated albumin is a better glycemic indicator than glycated hemoglobin values in hemodialysis patients with diabetes: effect of anemia and erythropoietin injection. J Am Soc Nephrol (2007) 18:896–903.[Abstract/Free Full Text]
  26. Peacock TP, Shihabi ZK, Bleyer AJ, et al. Comparison of glycated albumin and hemoglobin A(1c) levels in diabetic subjects on hemodialysis. Kidney Int (2008) 73:1062–1068.[CrossRef][Web of Science][Medline]
  27. Fukuoka K, Nakao K, Morimoto H, et al. Glycated albumin levels predict long-term survival in diabetic patients undergoing haemodialysis. Nephrology (2008) 13:278–283.[CrossRef][Medline]
  28. Imai E, Horio M, Nitta K, et al. Modification of the Modification of Diet in Renal Disease (MDRD) Study equation for Japan. Am J Kidney Dis (2007) 50:927–937.[CrossRef][Web of Science][Medline]
Received for publication: 29. 8.08
Accepted in revised form: 9.10.08


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Nephrol Dial TransplantHome page
W. van Biesen, S. Van Laecke, and R. Vanholder
Treatment of type 2 diabetes in chronic kidney disease: meekly follow the herd or call to arms?
Nephrol. Dial. Transplant., July 1, 2009; 24(7): 2286 - 2287.
[Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
M. K. Mani
Metformin in renal failure--weigh the evidence
Nephrol. Dial. Transplant., July 1, 2009; 24(7): 2287 - 2288.
[Full Text] [PDF]

This Article
Right arrow Extract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
24/2/338    most recent
gfn616v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Haneda, M.
Right arrow Articles by Morikawa, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Haneda, M.
Right arrow Articles by Morikawa, A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?